 Lineage Cell Therapeutics Inc NYSE: LCTX has entered into an exclusive worldwide collaboration and license agreement with Roche Holdings AGs OTC: RHHBY Genentech to develop and commercialize retinal pigment epithelium RPE cell therapy. Genentech will assume responsibility for further clinical development and commercialization of Lineages OpRegen program. 